公开(公告)号：US20140323395A1

公开(公告)日：2014-10-30

申请号：US14330495

申请日：2014-07-14

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A61K38/07 ,  A61K31/427 ,  A61K38/05

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/501 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7072 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。

公开(公告)号：US08680048B2

公开(公告)日：2014-03-25

申请号：US13656012

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A01N37/18 ,  A61K38/00 ,  A61P1/16 ,  A01N43/04 ,  A61K31/70

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US20130102526A1

公开(公告)日：2013-04-25

申请号：US13656012

申请日：2012-10-19

Applicant: ABBVIE INC.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A61K38/07 ,  A61P31/14 ,  A61K31/7068 ,  A61K31/7072 ,  A61K38/06

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/501 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7072 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).